-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the closing of its previously announced private placement with a single institutional investor of 3,773,585 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to an aggregate of 3,773,585 shares of common stock, for aggregate gross proceeds of $5.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company.
Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one warrant to purchase one share of common stock at a combined purchase price of $1.325. The warrants are exercisable for a period of five years from the date of issuance and have an exercise price of $1.325 per share.
Maxim Group LLC is acted as the sole placement agent for the offering.
Dermata currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act") and Regulation D promulgated thereunder and in a transaction not involving a public offering and have not been registered under the Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.
In connection with the private placement, Dermata entered into a registration rights agreement with the investor, whereby the Company has agreed to file one or more registration statements with the Securities and Exchange Commission (the "SEC") for the resale of the securities issued in the private placement, including the shares of common stock underlying warrants issued in the private placement.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dermata Therapeutics
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is in clinical development for the topical treatment of acne, psoriasis, and rosacea. Dermata's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit
Forward-Looking Statements
This release contains forward-looking statements regarding Dermata's business plans. The words "believe," "look forward to," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, but are not limited to: the proposed offering, including as to the completion of the private placement described above, the satisfaction of customary closing conditions related to the private placement and the intended use of net proceeds from the private placement, and other risks detailed and set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investors:
Sean Proehl
Senior Director, Legal and Business Development
info@dermatarx.com
SOURCE: Dermata Therapeutics
View source version on accesswire.com:
SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the closing of its previously announced private placement with a single institutional investor of 3,773,585 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to an aggregate of 3,773,585 shares of common stock, for aggregate gross proceeds of $5.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company.
加利福尼亚州圣迭戈/ACCESSWIRE/2022年4月25日/Dermata Treateutics,Inc.(“Dermata”或“公司”)(纳斯达克:DRMA)(纳斯达克:DRMAW)专注于治疗医疗和美容皮肤疾病的临床期生物技术公司亚洲网加利福尼亚州圣何塞10月23日电该公司今天宣布,在扣除配售代理费和公司应支付的其他发售费用之前,结束与单一机构投资者进行的3,775,585股普通股(或用于购买普通股的预先出资认股权证)和认股权证的私募,认股权证将购买总计3,775,585股普通股,总收益为500万美元。
Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one warrant to purchase one share of common stock at a combined purchase price of $1.325. The warrants are exercisable for a period of five years from the date of issuance and have an exercise price of $1.325 per share.
每股普通股(或代替普通股的预筹资金认股权证)与一份认股权证一起出售,以购买一股普通股,总购买价为1.325美元。这些认股权证的行使期为五年,由发行之日起计,行使价为每股1.325美元。
Maxim Group LLC is acted as the sole placement agent for the offering.
Maxim Group LLC是此次发行的唯一配售代理。
Dermata currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
德玛塔目前打算将此次发行的净收益用于营运资金和一般企业用途。
The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act") and Regulation D promulgated thereunder and in a transaction not involving a public offering and have not been registered under the Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.
上述证券是根据修订后的1933年《证券法》第4(A)(2)条和据此颁布的法规D以私募方式发行的,交易不涉及公开发行,也未根据该法或适用的州证券法进行登记。因此,证券不得在美国重新发售或转售,除非根据有效的注册声明或适用的豁免,不受该法和此类适用的州证券法的注册要求的约束。
In connection with the private placement, Dermata entered into a registration rights agreement with the investor, whereby the Company has agreed to file one or more registration statements with the Securities and Exchange Commission (the "SEC") for the resale of the securities issued in the private placement, including the shares of common stock underlying warrants issued in the private placement.
关于私募,德玛达与投资者订立了登记权协议,据此,本公司已同意向美国证券交易委员会(“美国证券交易委员会”)提交一份或多份登记声明,以转售于私募中发行的证券,包括于私募中发行的普通股相关认股权证股份。
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
本新闻稿不应构成出售要约或征求购买要约,也不应在任何州或司法管辖区出售这些证券,在这些州或司法管辖区,根据任何州或司法管辖区的证券法,在注册或获得资格之前,此类要约、征求或出售将是非法的。
About Dermata Therapeutics
关于皮肤治疗学
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is in clinical development for the topical treatment of acne, psoriasis, and rosacea. Dermata's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit
皮玛塔治疗公司是一家临床阶段的生物技术公司,专注于治疗医疗和美容皮肤疾病。该公司的主要候选产品DMT310是从其海绵技术平台。DMT310是一种每周一次的局部候选产品,来自天然来源的淡水海绵,具有多种独特的作用机制。DMT310正在临床开发中,用于局部治疗痤疮、牛皮癣和酒渣鼻。Dermata的第二个候选产品DMT410使用其海绵技术是一种局部皮内注射肉毒杆菌毒素的新方法,用于治疗多种美容和医疗皮肤病。德玛塔的总部设在加利福尼亚州的圣地亚哥。欲了解更多信息,请访问
Forward-Looking Statements
前瞻性陈述
This release contains forward-looking statements regarding Dermata's business plans. The words "believe," "look forward to," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, but are not limited to: the proposed offering, including as to the completion of the private placement described above, the satisfaction of customary closing conditions related to the private placement and the intended use of net proceeds from the private placement, and other risks detailed and set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
本篇新闻稿包含有关德玛塔公司商业计划的前瞻性陈述。“相信”、“期待”、“可能”、“估计”、“继续”、“预期”、“打算”、“应该”、“计划”、“可能”、“目标”、“潜在”、“很可能”、“将会”、“预期”以及类似的表述与我们有关,旨在识别前瞻性表述。这些陈述与未来事件或我们的财务表现有关,涉及已知和未知的风险、不确定性和其他因素,这些风险、不确定性和其他因素可能导致实际结果、表现或成就与前瞻性陈述明示或暗示的任何未来结果、表现或成就大不相同。这些因素包括但不限于:建议的发售,包括上述定向增发的完成、与定向增发相关的惯常成交条件的满足以及定向增发所得资金的预期用途,以及在公司提交给美国证券交易委员会的文件中详细列出的其他风险。告诫潜在投资者不要过度依赖此类前瞻性陈述,这些陈述仅在本新闻稿发布之日发表。公司不承担公开更新任何前瞻性陈述的义务,无论是由于新信息、未来事件还是其他原因。
Investors:
Sean Proehl
Senior Director, Legal and Business Development
info@dermatarx.com
投资者:
肖恩·普罗尔
董事高级法律和业务发展部
邮箱:Info@dermatarx.com
SOURCE: Dermata Therapeutics
资料来源:皮肤治疗学
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧